Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URLC10 + TTK + KOC1 + VEGFR1 + VEGFR2 + cisplatin + fluorouracil
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Peptides
- Administration
- Subcutaneous (for Vaccine), Intravenous (for Cisplatin And Fluorouracil)
01
Overview
This is a **combination therapy** investigated as treatment for cancer, particularly esophageal squamous cell carcinoma (ESCC). The regimen consists of a multi-peptide cancer vaccine containing five tumor-associated antigen peptide epitopes—derived from up-regulated lung cancer 10 (URLC10), TTK protein kinase (TTK), KOC1 (insulin-like growth factor II mRNA-binding protein 3), vascular endothelial growth factor receptor 1 (VEGFR1), and vascular endothelial growth factor receptor 2 (VEGFR2)—administered together with **cisplatin** and **fluorouracil**. The vaccine is designed to induce cytotoxic T lymphocyte responses against tumor cells expressing these antigens, stimulating an immune-mediated antitumor effect. The combination with cisplatin and fluorouracil, both standard chemotherapeutic agents, aims to potentiate antitumor activity via both immunological and cytotoxic mechanisms. Clinical trials have demonstrated safety and immunological activity for the peptide vaccine with chemoradiotherapy in ESCC, with evidence of cytotoxic T cell induction and complete responses in a subset of patients[1][3][7].
- Other names
- URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine + cisplatin + fluorouracil
02
Targets
DNAMHC I (MHC class I})TS (Thymidylate synthase)LCAA (Lung Cancer-Associated Antigen L523S)TTK (TTK protein kinase)LY6K (Lymphocyte antigen 6 complex locus protein K)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on URLC10 + TTK + KOC1 + VEGFR1 + VEGFR2 + cisplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URLC10 + TTK + KOC1 + VEGFR1 + VEGFR2 + cisplatin + fluorouracil.